FOMX - Foamix Pharmaceuticals Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.3100
-0.0400 (-1.70%)
At close: 4:00PM EDT

2.2982 -0.01 (-0.51%)
After hours: 4:05PM EDT

Stock chart is not supported by your current browser
Previous Close2.3500
Open2.3500
Bid2.2800 x 800
Ask2.3300 x 800
Day's Range2.3000 - 2.3700
52 Week Range2.2100 - 7.6000
Volume255,375
Avg. Volume289,750
Market Cap125.723M
Beta (3Y Monthly)2.06
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswirelast month

    Foamix Announces Publication of Phase 3 FMX101 Acne Study in Journal of American Academy of Dermatology

    REHOVOT, Israel and BRIDGEWATER, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), a clinical-stage pharmaceutical company that specializes in developing and commercializing proprietary topical therapies for dermatological conditions, announced today the peer review publication of the Phase 3 study FX2017-22 (“Study 22”) in the Journal of the American Academy of Dermatology (JAAD).  Study 22 was conducted by Foamix to support the New Drug Application (NDA) submission of FMX101, which is currently under review by the FDA for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients nine years of age and older. “We are pleased that the prestigious JAAD has chosen to highlight Study 22 in its current edition,” said Dr. Iain Stuart, Chief Scientific Officer of Foamix.  “The American Academy of Dermatology is the largest and most influential dermatology group in the United States and JAAD is the ideal platform to share the results from this successful Phase 3 study with the broader clinical dermatology community.

  • GlobeNewswire2 months ago

    Foamix Reports First Quarter 2019 Financial Results and Provides Corporate Update

    FDA Accepts NDA for FMX101, Sets October 20, 2019 as PDUFA Action Date Conference Call Scheduled for Wednesday May 8th at 8:30am Eastern Time REHOVOT, Israel and BRIDGEWATER,.

  • GlobeNewswire2 months ago

    Foamix Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019

    REHOVOT, Israel, and BRIDGEWATER, N.J., May 06, 2019 -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), clinical stage specialty pharmaceutical company focused on.

  • GlobeNewswire3 months ago

    Foamix to Present Late Breaking Data at the 77th Annual Meeting of the Society for Investigative Dermatology

    Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced it will present two late-breaking posters relating to its topical product candidate FMX101, a 4% minocycline foam being developed for the treatment of moderate-to-severe acne, at the 77th Annual Meeting of the Society for Investigative Dermatology to be held May 8-11, 2019, in Chicago, Illinois. Foamix  previously announced that the U.S. Food & Drug Administration (FDA) has accepted the filing of a New Drug Application for FMX101 for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients nine years of age and older and the FDA has set an action date of October 20, 2019 under the Prescription Drug User Fee Act (PDUFA).

  • GlobeNewswire3 months ago

    Foamix Pharmaceuticals First Quarter 2019 Financial Results Conference Call & Webcast Scheduled for May 8

    REHOVOT, Israel and BRIDGEWATER, N.J., April 24, 2019 -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on.

  • GlobeNewswire3 months ago

    Foamix Announces Settlement of Litigation with Perrigo Relating to Finacea Foam

    Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that, together with LEO Pharma, it has settled the Hatch-Waxman litigation with Perrigo, relating to Finacea® Foam. "Together with LEO Pharma, we are pleased to have settled the outstanding litigation with Perrigo," said David Domzalski, Chief Executive Officer of Foamix. Foamix is the owner of patents that have been licensed to LEO Pharma to market Finacea® Foam, a topical prescription medicine used to treat the inflammatory papules and pustules of mild to moderate rosacea.

  • GlobeNewswire4 months ago

    Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2019

    REHOVOT, Israel and BRIDGEWATER, N.J., March 08, 2019 -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on.

  • GlobeNewswire4 months ago

    Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne

    Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that the U.S. Food & Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for FMX101.  Foamix is seeking approval of FMX101 for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients nine years of age and older.  The FDA has set October 20th, 2019 as the Prescription Drug User Fee Act (PDUFA) action date.

  • GlobeNewswire4 months ago

    Foamix Pharmaceuticals to Present at the Cowen & Company 39th Annual Health Care Conference

    REHOVOT, Israel and BRIDGEWATER, N.J., March 06, 2019 -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on.

  • GlobeNewswire5 months ago

    Foamix Reports Fiscal Year 2018 Financial Results and Provides Corporate Update

    REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 28, 2019 -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty.

  • GlobeNewswire5 months ago

    Foamix Announces Positive Results from Phase 3 Open-Label Safety Study Evaluating FMX103 Topical Minocycline Foam for Treatment up to One Year

    Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced positive safety and efficacy data for its Phase 3 open-label safety study (FX2016-13), evaluating FMX103 in moderate-to-severe papulopustular rosacea for a treatment period of up to 1 year. The open-label safety study enrolled a total of 505 patients, all of whom had completed 12 weeks of FMX103 or vehicle treatment in the preceding double-blind studies (FX2016-11 or FX2016-12).

  • GlobeNewswire5 months ago

    Foamix -- with Late-Stage Candidates in Acne and Rosacea -- to Participate at American Academy of Dermatology Annual Meeting

    Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that it will participate in the American Academy of Dermatology (AAD) Annual Meeting to take place March 1 – 5, 2019 at the Walter E. Washington Convention Center, in Washington D.C. Clinical data on the Company’s late stage clinical development candidates, FMX101 for moderate to severe acne, and FMX103 for papulopustular rosacea, are expected to be covered in oral presentations by leading clinical dermatologists during the meeting.

  • GlobeNewswire5 months ago

    Foamix Pharmaceuticals Fourth Quarter Financial Results Conference Call & Webcast Scheduled for March 1

    REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 14, 2019 -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on.

  • GlobeNewswire6 months ago

    Foamix Announces Appointment of Sharon Barbari to Board of Directors

    Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the appointment of Sharon Barbari to its Board of Directors. “I am honored to join Foamix’s Board of Directors and I look forward to helping guide the company through its anticipated upcoming pivotal milestones for its lead candidates FMX101 and FMX103,” said Ms. Barbari. Ms. Barbari joins Foamix’s Board with over 40 years of pharmaceutical and biotechnology experience.

  • GlobeNewswire7 months ago

    Foamix Submits New Drug Application to U.S. FDA Seeking Approval of FMX101 in Treatment of Moderate-to-Severe Acne

    Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for FMX101 for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. “Submission of this NDA is yet another important milestone for Foamix, and potentially brings us one step further to commercial launch of FMX101,” commented David Domzalski, Chief Executive Officer.

  • GlobeNewswire8 months ago

    Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer

    Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the appointment of Matt Wiley as Chief Commercial Officer. “Matt has an exceptional commercial record in pharmaceuticals and brings valuable experience and depth of knowledge in marketing, market access, and product launches,” said David Domzalski, Chief Executive Officer of Foamix. Matt Wiley joins Foamix with more than 20 years of commercial experience across a broad range of specialty pharmaceutical categories.

  • GlobeNewswire8 months ago

    Foamix Announces Appointment of Anthony Bruno to Board of Directors

    Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the appointment of Anthony Bruno to its Board of Directors, replacing Darrell Rigel, M.D. who has resigned from the Board and will become a consultant to the company. “We are delighted to welcome Tony to our Board of Directors,” said Dr. Stanley Hirsch, Chairman of the Board of Foamix.

  • GlobeNewswire8 months ago

    Recent Analysis Shows WPX Energy, Verizon Communications, Innovative Industrial Properties, Foamix Pharmaceuticals, O2Micro International, and Investment Technology Group Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire8 months ago

    Foamix Reports Third Quarter 2018 Financial Results and Provides Corporate Update

    Conference Call and Webcast Thursday, November 8, @ 8.30 am Eastern Time REHOVOT, Israel, Nov. 07, 2018 -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the.

  • GlobeNewswire8 months ago

    Foamix Announces Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea

    FMX103 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both Co-Primary Efficacy Endpoints Conference Call and Webcast Today at 8:30.